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Drug resistance and toxicity constitute challenging hurdles for
cancer therapy. The application of nanotechnology for anticancer
drug delivery is expected to address these issues and bring new
hope for cancer treatment. In this context, we established an
original nanomicellar drug delivery system based on an amphi-
philic dendrimer (AmDM), which could generate supramolecular
micelles to effectively encapsulate the anticancer drug doxorubicin
(DOX) with high drug-loading capacity (>40%), thanks to the
unique dendritic structure creating large void space for drug ac-
commodation. The resulting AmDM/DOX nanomicelles were able
to enhance drug potency and combat doxorubicin resistance in
breast cancer models by significantly enhancing cellular uptake
while considerably decreasing efflux of the drug. In addition, the
AmDM/DOX nanoparticles abolished significantly the toxicity re-
lated to the free drug. Collectively, our studies demonstrate that
the drug delivery system based on nanomicelles formed with the
self-assembling amphiphilic dendrimer constitutes a promising and
effective drug carrier in cancer therapy.
amphiphilic dendrimers | supramolecular nanomicelles | drug delivery |
cancer treatment | nanodrugs
Although considerable progress has been made in cancertherapy, the complete cure and eradication of cancer remains
one of the greatest challenges at present. A well-known hurdle is
the drug resistance induced by chemotherapeutics, causing high
recurrence rate and therapeutic failure (1). Moreover, high sys-
temic toxicity of traditional anticancer drugs is another reason for
eventual poor clinical outcome. To address these problems, the
application of nanotechnology for drug delivery is widely expected
to bring new hope for cancer treatment (2–6). Nanoparticle-based
drug delivery systems can repress many drawbacks of traditional
chemotherapeutics, such as high systematic toxicity and low ther-
apeutic efficacy caused often by poor drug bioavailability, fre-
quently related to the stability, solubility, and nonspecificity of
drugs (2–8). In addition, nanodrugs with tailored properties can
overcome drug resistance by increasing the drug accessibility and
drug sensitivity via high local drug concentration achieved at
tumor lesion through enhanced permeation and retention (EPR)
effect (9–11). As a result, there is an increasing interest to develop
effective nanodrugs for cancer treatment, and some of such systems
have already made their way to clinical trials (2, 12, 13).
Among various nanotechnology-based drug delivery systems,
such as liposomes, nanomicelles, and nanotubes (7, 8, 14),
nanomicelles have gained particular interest in cancer therapy by
virtue of their appealing advantages such as high drug loading for
effective therapeutic potency and small size (<30 nm) for deep
tumor penetration (15, 16). The most common nanomicelles are
constructed with lipids and amphiphilic polymers (12, 13).
However, lipid-based nanomicelles have the drawback of limited
stability, whereas polymers are plagued with dispersed molecular
weight distribution. An optimal nanomicelles-based delivery system
is expected to combine the advantages of lipid and polymer vectors
while overcoming their shortcomings.
We have been particularly interested in establishing novel
nanomicellar drug delivery platform based on amphiphilic den-
drimers, i.e., hybrid molecules composed of a hydrophobic lipid
entity entailing molecular self-assembly in a water environment,
and a hydrophilic dendritic polymer component. Thus, nano-
assemblies formed by amphiphilic dendrimers are able to com-
bine the stability and mechanical strength of dendrimeric polymers
and the micelle-forming feature of lipids (17). In addition, owing to
the unique radiate dendritic structure, the nanomicelles composed
by dendrimer amphiphiles harbor large void space within their inner
cores, which can be harnessed for high drug-loading efficiency (Fig.
1A). Here, we report a nanomicelle-based drug delivery system
generated by the dendritic amphiphile AmDM (Fig. 1B). Not-
withstanding their small size (10 nm), these nanomicelles can
carry the anticancer drug doxorubicin (DOX) at very high payload
efficiency. The resulting AmDM/DOX system can effectively
enhance anticancer drug efficiency and combat drug resistance
through a combination of promoted cellular uptake and decreased
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drug efflux. Moreover, AmDM/DOX nanomicelles can signifi-
cantly increase the therapeutic potency and reduce the systemic
toxicity of doxorubicin in vivo by virtue of preferential tumor
targeting via EPR effect alongside with deeper tumor penetra-
tion. This original nanomicelle delivery system based on the self-
assembling amphiphilic dendrimer constitutes therefore a prom-
ising and effective drug carrier in cancer therapy.
Results and Discussion
Amphiphilic Dendrimer-Based Nanomicelles Encapsulate Doxorubicin
with Small Size and High Drug Payload. The amphiphilic dendrimer
AmDM used in this work (Fig. 1B) bears a small hydrophilic
poly(amidoamine) (PAMAM) (18, 19) dendron and two hy-
drophobic C18 alkyl chains bridged via click chemistry (20, 21).
Using the film dispersion method, AmDM could easily form
nanomicelles, as revealed by transmission electron microscopy
(TEM) imaging (Fig. 2A) and dynamic light-scattering (DLS)
analysis (Fig. 2B). The so-formed AmDM assemblies were
spherical in shape (6.8 nm in diameter) and well-dispersed
[polydispersity index (PDI): 0.21 ± 0.02] with a critical micelle
concentration (CMC) of 3.2 μM (Fig. S1A). Computer simu-
lations also predicted the aggregation of AmDM into small,
spherical micelles, as shown in Fig. S2A. Insights into the
structural properties of these micelles were further gained by
performing mesoscale computational studies using dissipative
particle dynamics (DPD) (22), a well-established technique in
soft matter simulations to study amphiphilic systems at the
nanoscale (23–25). These simulations highlighted the hydro-
phobic nature of the micellar core (Fig. 2C), whose average size
Rcore was estimated to be 1.3 ± 0.2 nm. The hydrophilic portion
of the micelles then forms a corona, shielding the core from the
solvent environment, as proven by the corresponding density
distribution profiles illustrated in Fig. 2D. The overall micellar
radius Rm derived from DPD calculations was Rm 3.1± 0.3 nm, in
line with the DLS and TEM results.
We next constructed the anticancer drug DOX encapsu-
lated AmDM assemblies using the same film-dispersion method.
Gratifyingly, the resulting AmDM/DOX systems also consisted
in spherical nanoparticles with a size of ∼10 nm (PDI: 0.32 ±
0.01) (Fig. 2 E and F). It is important to mention that small-sized
nanoparticles are particularly beneficial for drug delivery in
cancer therapy because they can successfully avoid kidney ex-
cretion and spleen sequestration; concomitantly, they are able to
accumulate at tumor site and penetrate deeper into the inner
regions of tumor lesions (16, 26, 27). Indeed, biodistribution
experiments using a near-infrared fluorescent dye, DiR, dem-
onstrated that the AmDM nanosystem had a longer circulation
time, and was effectively accumulated and retained in the tumor
(Fig. 2I and Fig. S3)—evidence that could indeed be ascribed to
the EPR effect. Further drug penetration experiments using 3D-
cultured tumor spheroids unambiguously showed that, by virtue of
their small size, the AmDM/DOX nanomicelles could effectively
penetrate deeper into the interior of the tumor spheroids with re-
spect to free DOX (Fig. 2J). These data were further supported by
the tumor penetration results obtained in vivo (Fig. S4).
Also of note is that the AmDM/DOX nanoparticles were
slightly larger in size than the empty AmDM micelles, as evi-
denced by both TEM image and DLS analysis (Fig. 2 A, B, E,
and F). This size difference could be reasonably ascribed to a
micellar expansion required to accommodate doxorubicin within
the hydrophobic micellar core to reach high loading (Fig. 1A).
In silico mesoscale simulations confirmed that DOX-loaded
AmDM micelles still exhibited a spherical core/shell architecture
(Fig. 2G), with an average micellar radius Rm of 4.6 ± 0.2 and
hydrophobic core radius Rcore of 2.5 ± 0.2 nm, respectively. The
distribution of DOX inside each micelle was also obtained by
plotting the relative density profiles. As shown in Fig. 2H, the dis-
tribution of the drug is consistent with that of the core segments,
confirming that DOX is predominantly entrapped in the hydro-
phobic core of the micelle. Accordingly, these results confirm the
hypothesis outlined above that the slight increase in micellar
dimensions upon drug loading could be substantially ascribed to the
increase of its inner core to accommodate the high DOX payload.
We further investigated drug-loading content and encapsula-
tion efficiency of the AmDM/DOX micelles by varying den-
drimer/drug ratio. The maximal drug-loading efficiency could be
attained up to 42% (Fig. S2B). This high drug-loading capacity
can stem from the unique lipid/dendrimer hybrid molecular
structure of AmDM, which, by virtue of its branched dendritic
hydrophilic component, generates micelles with low-density hy-
drophobic cores large enough to accommodate considerable
amounts of drug payloads.
Drug Release from AmDMNanomicelles Is Enhanced in Acid Environment.
A key point of a performing drug delivery system in cancer therapy
is the controlled release of the therapeutic agent at the tumor site,
reducing the toxicity to normal tissues. Tumor lesions are usually
more acidic than normal tissues because of hypoxia microenviron-
ment and acidic organelles of cancer cells; therefore, acid-promoted
drug release is a beneficial advantage in cancer therapy (28, 29). We
hence assessed doxorubicin release from the AmDM/DOXmicelles
under acidic condition (pH 5.0) in contrast to the neutral physio-
logical pH 7.4. As exhibited in Fig. 2K, doxorubicin release from
AmDM/DOX nanomicelles at pH 5.0 was more rapid and efficient
than that at pH 7.4. This evidence could be rationalized taking
into account the well-known proton sponge effect of the PAMAM
dendrimer component of AmDM (20, 21). Indeed, at physiological
condition (pH 7.4), only the terminal primary amines of the
PAMAM dendron are protonated, but under acidic environment
(pH 5.0), the tertiary amines in the interior of the dendron also
Fig. 1. Nanomicelles constructed with AmDM as a drug delivery platform.
(A) Formation of empty AmDM nanomicelles and DOX-encapsulated AmDM/
DOX nanomicelles. (B) Molecular structure of amphiphilic dendrimer AmDM.
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become protonated, making the entire dendrimer entity highly
positively charged (Fig. S1B); this, in turn, generates intense elec-
trostatic repulsion among the dendrimer branches, ultimately
leading to enhanced drug release. In addition, the encapsulated
amine-bearing DOX can be more favorably charged at pH 5.0 than
at pH 7.4; this would contribute extra electrostatic repulsion and
further facilitate drug release under acidic condition. This acid-
promoted drug release feature will endow the AmDM/DOX
system with a preferential drug release profile at acidic tumor
lesions rather than in normal tissues at neutral pH.
AmDM/DOX Nanomicelles Show Enhanced Antiproliferation Efficiency
via Rapid and Effective Cellular Uptake. Impelled by the favorable
drug release profile of AmDM/DOX nanomicelles, we went on
to evaluate their antiproliferation efficiency in various cancer
cells, including DOX-sensitive breast cancer MCF-7S cells, DOX-
resistant breast cancer MCF-7R cells, castration-resistant prostate
cancer PC-3 cells, hepatoma HepG2 cells, and cervical cancer HeLa
cells (Fig. 3 and Fig. S5). In all cases, the antiproliferation effect of
AmDM/DOX was much higher than that exerted by the clinical
anticancer drug DOX and by the clinical DOX nanodrug Caelyx
(Fig. 3 and Fig. S5). Specifically, in both DOX-sensitive MCF-7S
cells and resistant MCF-7R cells, the IC50 values of AmDM/DOX
(0.62 and 2.0 μM, respectively) were much lower than those of free
DOX (6.1 and >100 μM) and of Caelyx (>100 μM). These results
clearly demonstrated that AmDM/DOX micelles were considerably
more effective than free drug DOX and nanodrug Caelyx in re-
ducing cell proliferation in both drug-sensitive and drug-resistant
cell lines, ultimately leading to apoptosis induced anticancer
activity (Fig. S6).
Fig. 2. AmDM self-assembles into nanomicelles with a large void space in their inner core available for DOX encapsulation. (A) TEM image and (B) DLS
analysis of AmDM nanomicelles. (C) Detailed mesoscale morphology of AmDM micelles. Micellar hydrophilic shell and hydrophobic core are highlighted as
purple and pink sticks, respectively. Solvent is depicted as light blue field. (D) Density distributions of AmDM hydrophobic core (pink dots) and hydrophilic
shell (purple dots) segments as a function of distance from the center of the micelle. (E) TEM image and (F) DLS analysis of AmDM/DOX nanomicelles.
(G) Detailed mesoscale morphology of AmDM/DOX micelles: AmDM micelles and solvent represented as in D; DOX shown as green spheres. (H) Density
distributions of AmDM hydrophobic core (pink dots), hydrophilic shell (purple dots) segments, and DOX (green dots) as a function of distance from the center
of the micelle. (I) Fluorescent imaging of biodistribution of AmDM nanomicelles loaded with a near-infrared fluorescent dye, DiR, 48 h postadministration via i.v.
injection in NSG mice bearing MCF-7R tumors. (J) Drug penetration of AmDM/DOX nanomicelles into 3D-cultured MCF-7R tumor spheroids imaged with
a two-photon microscope. (K) Time course of DOX released from AmDM/DOX micelles at pH 5.0 and pH 7.4 at 37 °C.
Fig. 3. AmDM/DOX nanomicelles show enhanced antiproliferation efficiency via rapid and effective cellular uptake. The antiproliferative activity of free DOX, DOX
nanodrug Caelyx, and AmDM/DOX nanomicelles on (A) drug-sensitive breast cancer MCF-7S cells and (B) drug-resistant breast cancer MCF-7R cells was measured
using an MTT assay. The cellular uptake in (C) MCF-7S and (D) MCF-7R cells was quantified using flow cytometry after treatment with DOX and AmDM/DOX,
respectively. (E) The cellular uptake was imaged using confocal microscope following treatment with free DOX and AmDM/DOX in MCF-7R cells. (Scale bar: 10 μm.)
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To understand the mechanisms underlying the enhanced
antiproliferation activity of AmDM/DOX nanomicelles, we first
inspected their uptake in both MCF-7S and MCF-7R cells using
flow cytometry. Effectively, doxorubicin-encapsulated nano-
micelles promoted the internalization and accumulation of doxo-
rubicin in a dose- and time-dependent manner (Fig. 3 C and D);
this was particularly significant in doxorubicin-resistant MCF-7R
cells, where the cellular uptake was much faster and more ef-
fective with AmDM/DOX than with the free DOX. Indeed, the
drug uptake in MCF-7R cells was practically null with free DOX
after 2-h treatment (Fig. 3D); by contrast, the AmDM/DOX
system could rapidly enter MCF-7R cells and led to substantial
intracellular drug accumulation. This enhanced cellular uptake
of AmDM/DOX in MCF-7R cells was further confirmed by
confocal laser scanning microscopy (Fig. 3E). Collectively, these
results suggest that AmDM/DOX nanomicelles successfully en-
ter into both drug-resistant and drug-sensitive cancer cells via
a rapid and efficient internalization.
Further subcellular localization results showed that the doxo-
rubicin fluorescence was partly colocalized with lysosomes, in-
dicating that the AmDM/DOX nanomicelles were internalized
and entered the lysosomes. Moreover, doxorubicin fluorescence
was also observed in the cytoplasm, suggesting that the drug
could successfully escape from the lysosomes into the cytoplasm
(Fig. S7); this was mainly ascribed to the acidic environment of
lysosomes (pH 4.0–5.0). As discussed previously, under these
conditions, doxorubicin release from the AmDM micelles can
indeed be facilitated by a combination of pH-dependent drug
release and proton sponge effect of nanocarriers. Finally, the
released doxorubicin from AmDM/DOX nanomicelles could
effectively enter into nuclei (Fig. 3E), leading to the concrete
anticancer activity. Together, these results qualify AmDM/DOX
nanomicelles as promising drug delivery systems for cancer
therapy, which significantly increase anticancer drug potency,
even in drug-resistant cancer cells, through effectively enhanced
drug uptake via nanoparticle formation.
AmDM/DOX Nanomicelles Combat Drug Resistance via Bypassing
Drug Efflux Pumps and Inhibiting Drug Efflux. Drug resistance is
often associated with the drug efflux pumps overexpressed on the
cell membrane (30, 31). P-glycoprotein is reported to be the
major efflux pump overexpressed on drug-resistant MCF-7R
cells, opposing the cellular uptake of free DOX (32). The rapid
and effective cell uptake of AmDM/DOX nanomicelles in MCF-7R
is indicative of a nanoparticle-based cellular uptake pathway,
which could bypass P-glycoprotein. We therefore investigated
the uptake mechanism of AmDM/DOX nanomicelles using
various endocytosis inhibitors (33) (Fig. 4A). Cytochalasin D (CD),
an inhibitor of macropinocytosis-dependent endocytosis, signifi-
cantly inhibited the internalization of AmDM/DOX in a dose-
dependent manner, whereas neither genistein (an inhibitor of
caveolae-mediated endocytosis) nor chlorpromazine (CMZ), an
inhibitor of clathrin-mediated endocytosis, showed any notable
inhibition on the cellular uptake (Fig. 4A). These results suggest
that macropinocytosis was the main uptake mechanism by which
AmDM/DOX could successfully bypass the recognition and
capture of efflux proteins, contributing to the effective uptake of
doxorubicin in drug-resistant cancer cells.
It is also of note that P-glycoproteins are able to efflux a broad
variety of structurally and functionally distinct anticancer drugs,
preventing adequate drug accumulation in cancer cells and, thus,
leading to drug resistance (34). We therefore assessed the drug
efflux in drug-resistant MCF-7R cells using flow cytometry. The
result showed that most of the free DOX was eliminated from
MCF-7R cells within 1 h, whereas little doxorubicin carried
by AmDM/DOX nanomicelles was expelled even after 8 h (Fig.
4B). These results highlighted that doxorubicin encapsulated
into AmDM/DOX nanoparticles could effectively escape the
drug efflux action of the P-glycoprotein. Overall, the enhanced
Fig. 4. AmDM/DOX nanomicelles overcome drug resistance via macro-
pinocytosis-mediated endocytosis and inhibition of drug efflux. (A) In-
hibition of the uptake of AmDM/DOX micelles on MCF-7R cells using specific
endocytosis inhibitors. CD: inhibitor of macropinocytosis; genistein: inhibitor
of caveolae-mediated endocytosis; CMZ: inhibitor of clathrin-mediated en-
docytosis. (B) Inhibition of doxorubicin efflux by AmDM/DOX nanomicelles
was determined in MCF-7R cells.
Fig. 5. Proposed mechanism to elude drug resistance by AmDM/DOX micelles
in doxorubicin-resistant breast cancer MCF-7R cells.
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anticancer activity of AmDM/DOX could be primarily attributed
to the significantly promoted cellular uptake and considerably
decreased efflux of doxorubicin (Fig. 5).
Potent Anticancer Effect and Significantly Reduced Systemic Toxicity
of AmDM/DOX Nanomicelles. Encouraged by the promising in vitro
results obtained with AmDM/DOX, alongside the good blood
compatibility and nontoxic features of AmDM (Fig. S8), we
performed in vivo experiments by assessing the tumor growth
inhibition exerted by the AmDM/DOX nanomicelles in NOD
scid gamma (NSG) mice bearing s.c. tumors derived from drug-
resistant breast cancer MCF-7R cells. As shown in Fig. 6A, ad-
ministration of free DOX only moderately retarded the tumor
growth at high dosage (5.0 mg/kg), whereas little inhibition on
tumor growth was observed at 2.5 mg/kg. However, treatment
with AmDM/DOX nanomicelles significantly inhibited tumor
growth at both dosages (2.5 and 5.0 mg/kg), which was further
supported by the immunohistochemical (IHC) analysis to eval-
uate tumor cell proliferation. As shown in Fig. 6D, the Ki-67 level
of AmDM/DOX treatment groups was much lower than those of
other treatment groups, indicating lower cell proliferation in
tumors and hence higher antitumor activity of AmDM/DOX.
The markedly improved anticancer efficacy of the AmDM/DOX
system can be ascribed to the beneficial nanomicellar formula-
tion of DOX. Indeed, AmDM nanomicelles cannot only accu-
mulate more efficiently at the tumor lesion via the EPR effect
but also penetrate deeper within the tumor (Fig. 2 I and J and
Figs. S3 and S4), generating higher local concentration of anti-
cancer drug at the tumor site and, ultimately, exhibiting better
antitumor activity compared with free drug.
During the entire treatment period, the mice treated with
PBS, AmDM, and AmDM/DOX did not show any abnormal
behavior, and no significant alteration of mice body weight (Fig.
6B) was observed. In contrast, considerable weight loss was
registered in mice treated with free DOX (Fig. 6B). Moreover,
due to the high toxicity of free DOX (35–37), only one mouse
treated with the lower DOX dose of 2.5 mg/kg survived the
treatment period (Fig. 6C). To further assess the associated
toxicity of different treatments, we performed histological stud-
ies using hematoxylin-eosin-safran (HES) staining method. For
the mice administrated with free DOX, hyperemia and myo-
cardial fiber breakage was observed, especially at the high dose
of 5.0 mg/kg (Fig. 6E), suggesting possible cardiotoxicity associ-
ated with DOX (35–38). Liver damage was also detected in mice
treated with 5.0 mg/kg free DOX (Fig. S9). In contrast, no visible
tissue damage was observed in AmDM/DOX treatment groups
(Fig. 6E and Fig. S9). The drastically reduced toxicity of AmDM/
DOX can be reasonably explained by the nanomicellar formu-
lation of DOX, which can preferentially accumulate in the tumor
via EPR effect, thus reducing possible toxicity in normal tissues.
Collectively, these results confirm that AmDM/DOX nano-
micelles effectively improve DOX therapeutic effect while re-
ducing its systemic toxicity via the EPR effect.
Conclusions
In this work, we disclosed an original supramolecular nano-
micellar system based on the amphiphilic dendrimer AmDM,
which is able to effectively deliver the clinical anticancer drug
DOX, enhance anticancer activity, and combat drug resistance
while obviating systemic toxicity. This AmDM/DOX nanomicelle
features several favorable advantages as therapeutic options
in cancer therapy, including (i) high drug loading. This property
is primarily ascribable to the unique dendritic structure which,
upon self-assembly, results in micelles with large, low-density
hydrophobic core able to accommodate substantial amount of
drugs; (ii) small micellar size (10 nm) with narrow size distribution;
Fig. 6. AmDM/DOX nanomicelles significantly enhanced anticancer activity and reduced toxicity in tumor-xenograft mice. NSG mice were treated with free
DOX and AmDM/DOX at doxorubicin dose of 2.5 and 5.0 mg/kg via i.v. administration (twice per week, n = 7). PBS, AmDM groups were used as control (n = 7).
(A) Tumor volume and (B) mice body weight were measured twice per week. (C) Mice survival curves of different treatments. (D) Ki-67 IHC staining of tumor
tissues to assess tumor proliferation. (E) Histological analysis of heart was determined to evaluate the toxicity.
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such small-sized nanoparticles favor deeper penetration into
inner tumor regions and concurrently prolong overall circulation
time for beneficial accumulation in tumor tissue via EPR effect;
(iii) rapid and effective cellular uptake mainly via boosted
macropinocytosis; (iv) enhanced drug release at acidic pH,
leading to advantageously promoted drug release at tumor
lesions, normally more acidic than healthy tissues; and (v) effective
inhibition of drug efflux. Based on these multiple advantages,
AmDM/DOX micelles can effectively enhance DOX therapeutic
efficacy and combat drug resistance. Concomitantly, AmDM/
DOX nanomicelles can drastically reduce the systemic toxicity of
doxorubicin in vivo through preferential delivery at tumor site via
combined EPR effect and acid-promoted drug release. Given
these encouraging results, this drug delivery system based on
amphiphilic dendrimer AmDM constitutes a concrete promise as
a therapeutic entity in cancer treatment.
Materials and Methods
A full description of the materials and methods is provided in SI Materials
and Methods.
AmDM/DOX Nanomicelles: Preparation, Characterization, in Vitro Anticancer
Activity, Cell Uptake, and Drug Efflux Inhibition. AmDM/DOX nanomicelles
were prepared using film-dispersion method and characterized for size,
morphology, drug-loading, and drug-release properties using DLS, TEM, and
fluorescent spectroscopy. The antiproliferation activities of AmDM/DOX
against different cancer cell lines were evaluated using an MTT assay. Cell
uptake and drug efflux inhibitory effect of AmDM/DOX were studied using
flow cytometry and confocal fluorescent microscope. For further details,
please see SI Materials and Methods.
Deeper Tumor Penetration of AmDM/DOX Nanomicelles. Multicellular tumor
spheroids constructed with MCF-7R cells were incubated with AmDM/DOX,
then analyzed using a two-photon microscope by scanning the tumor
spheroids step-by-step with 10 μm thickness to obtain Z-stack images. For
further details, see SI Materials and Methods.
In Vivo Anticancer Activity Assay, in Vivo Biodistribution, in Vivo Toxicity Assay,
Immunohistochemistry, and HES Staining. Animal experiments were performed
in agreement with the Animal Ethics Committee of the Bouche du Rhône pre-
fecture in France and the institutional Animal Care and Use Committee of Peking
University in China. Mice bearing subcutaneous tumors derived from MCF-7R
cells were treated with AmDM/DOX via tail vein injection, with PBS, empty
AmDM, and free DOX as control groups. Mouse body weight was recorded
and tumor volume was measured to assess anticancer activity and possible
toxicity. In vivo biodistribution, in vivo toxicity assay, immunohistochemistry,
and HES staining were performed as described in SI Materials and Methods.
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